New drug combo for advanced non-squamous lung cancer patients
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new drug (HS-20093) alone versus combined with another drug (adebrelimab) for people with advanced or metastatic non-squamous non-small cell lung cancer who have already been treated. The goal is to see if the combination works better at shrinking tumors or slowing cancer growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You have non-squamous non-small cell lung cancer that has spread or is advanced, and you have already received treatment for it.
- You are able to do your daily activities with little or no help (performance status 0 or 1).
- Your cancer must not have spread to your brain or spinal cord, or if it has, it must be treated and controlled.
- You have not been treated with certain previous drugs, like docetaxel or a type of drug called a topoisomerase I inhibitor.
- You do not have active infections like hepatitis B, hepatitis C, HIV, or tuberculosis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination of drugs (HS-20093 plus adebrelimab) against a standard chemotherapy (docetaxel) for people with advanced or metastatic non-squamous non-small cell lung cancer who have already had treatment. The goal is to see if the new combination is more effective and safer than the standard chemo.
This trial tests a new drug combined with other treatments for people with lung cancer that can be removed by surgery. It aims to see if the treatment shrinks tumors before surgery and improves outcomes.
This trial tests a new drug called HS-10370 combined with other anti-cancer treatments for people with advanced lung cancer that has a specific genetic change (KRAS G12C). The goal is to see if this combination can shrink or control tumors better than other options.
This trial tests a new study drug called PF-08634404 combined with standard chemotherapy for people with advanced lung cancer that has not been treated before. It aims to see if this combination works better than chemotherapy alone.
This trial is comparing a new combination of two immunotherapy drugs (nivolumab and relatlimab) plus chemotherapy against the standard immunotherapy (pembrolizumab) plus chemotherapy for people with advanced non-squamous non-small cell lung cancer that has a certain protein (PD-L1) on at least 1% of its cells. The goal is to see if the new combination works better.
This trial tests a new combination of drugs (an immunotherapy and a possible new treatment) plus chemotherapy for people with advanced lung cancer. The goal is to see if this combination can shrink tumors or stop them from growing.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.